Ultrasensitive Circulating Tumor DNA Improves NSCLC Detection
JUN 13, 2024 Ultrasensitive circulating tumor DNA (ctDNA) detection appears to improve the clinical sensitivity of minimal residual disease (MRD) at key landmarks in early stage non-small cell lung cancer (NSCLC), researchers reported at the 2024 ASCO Annual Meeting. “PhasED-Seq detected MRD at levels below one ppm and was associated with significantly better outcomes, revealing potential benefits […]
PhasED-Seq™ MRD Detection: Accurate & Early Cancer Monitoring
Nov 28, 2023 AURORA, Colo., Nov. 8, 2023 /PRNewswire/ – Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection testing, announced today that six studies utilizing their patented PhasED-Seq™ technology will be presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH 2023) taking place December 9-12, 2023, in San Diego, California. Four of these studies have been […]
Ultivue announces launch of new configurable multiplex spatial panels at the Society for Immunotherapy of Cancer 2023 meeting
Oct 30, 2023 CAMBRIDGE, Mass., Oct. 30, 2023 /PRNewswire/ — Ahead of the 38th annual meeting of the Society for Immunotherapy of Cancer (SITC), Ultivue today announced the launch of OmniVUE™, a unique portfolio of fully customizable biomarker panels for multiplex immunofluorescence analysis of the tumor immune microenvironment. Researchers can now select any combination of up to 8 […]
Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform
Apr 27, 2023 AURORA, Colo., April 27, 2023 /PRNewswire/ — Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University… Read the full article […]
Molecular Designs releases their new Simplicity™ Gastrointestinal Pathogen Panel
Apr 11, 2023 BIRMINGHAM, Ala., April 11, 2023 /PRNewswire/ — Molecular Designs, a developer and manufacturer of molecular infectious disease assays, announces the release of its new Simplicity™ Gastrointestinal Pathogen Panel for the detection of causative agents of gastrointestinal (GI) tract infections. Simplicity Panels are pre-pipetted, polymerase chain reaction (PCR) assays provided in a unique breakaway […]
Foresight Diagnostics & leading cancer center to present solid tumor MRD data at AACR conference
Apr 04, 2023 AURORA, Colo., April 4, 2023 /PRNewswire/ — Foresight Diagnostics, a leader in molecular cancer diagnostics, announced the presentation of a study in collaboration with a leading cancer center at the upcoming annual meeting of the American Association for Cancer Research (AACR)… Read the full article on PR Newswire.
Factorial Biotechnologies collaborates with Watchmaker Genomics to dramatically simplify single-cell sequencing
Mar 28, 2023 SAN CARLOS, Calif., March 28, 2023 /PRNewswire/ — Factorial Biotechnologies, an emerging single-cell sequencing company with a novel intracellular library preparation technology, has announced a collaboration with Watchmaker Genomics, a life sciences company that specializes in developing high-stringency applications for reading, writing, and editing of DNA and RNA… Read the full article on […]
Spatial Biology CRO Flagship Biosciences Acquires Pharma Services Business from Interpace Biosciences
Aug 31, 2022 Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma Solutions® (“IPS”), a division of Interpace Biosciences and provider of cytogenetic, molecular pathology, and genomic profiling solutions. This acquisition follows a growth equity investment in Flagship from Ampersand Capital Partners, BroadOak Capital Partners, and […]
Foresight Diagnostics Announces the Hiring of Sandra Close, Ph.D., as Chief Operations Officer
Apr 04, 2022 Foresight Diagnostics today announced the hiring of Sandra Close, Ph.D., as Chief Operations Officer (COO). Sandra brings extensive experience in delivering drugs and diagnostics, with a focus on organizational structure, business strategy, and quality and regulatory requirements. Dr. Close has served as an executive leader in both diagnostic and pharmaceutical companies, including […]
Foresight Diagnostics Expands Scientific Advisory Board with Appointment of Christopher R. Flowers, M.D., M.S.
Apr 27, 2022 Foresight Diagnostics today announced the appointment of Christopher R. Flowers, M.D., M.S., to its Scientific Advisory Board (SAB). Dr. Flowers is an oncologist specializing in the treatment of B cell lymphoma and rare subtypes of lymphoma. He currently serves as Chair and Professor in the Department of Lymphoma-Myeloma in the Division of Cancer […]
